Refractory gynecological malignancies
Conditions
Interventions
Refractory gynecological malignancies:N/A
Sponsors
Zhejiang Cancer Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.Pathologically confirmed gynecological malignant tumors (including cervical cancer, endometrial cancer, vaginal cancer, vulvar cancer, ovarian cancer, and other malignant tumors of special gynecological pathological types); 2.Recurrent/metastatic or advanced primary gynecological malignancies, with lesions unresponsive to conventional photon radiotherapy; 3.The patient's condition has been discussed within the department and with the hospital’s multidisciplinary team (MDT), and carbon ion radiotherapy is indicated; 4.The patient voluntarily agrees to receive carbon ion radiation therapy at Zhejiang Cancer Hospital and assumes the related costs; 5.Pelvic MRI imaging data within 2 weeks before radiotherapy; pelvic MRI imaging data after 20 fractions of external radiotherapy (prior to brachytherapy); pelvic MRI imaging data within 1 month after completion of pelvic radical dose radiotherapy and at 3 months and 6 months post-radiotherapy. 6.Complete clinical and imaging data; 7.The patient is willing to participate in the study and accept questionnaire surveys; 8.The patient is willing to participate in the study and provide tissue and various body fluid samples; 9.The patient is willing to undergo regular follow-up in the hospital’s outpatient department.
Exclusion criteria
Exclusion criteria: 1.Previous history of >=2 pelvic external radiotherapy sessions (pelvic field recurrence); 2.Received any radioactive particle implantation treatment within the treatment area; 3.The dose limits for critical organs cannot meet the preset safety dose; 4.Presence of metal implants along the radiation field path that may affect the accuracy of radiotherapy dose calculation; 5.The patient has had or currently has any other second primary malignancies; 6.Lack of pathological confirmation of the primary lesion; 7.The possibility of double primary or multiple primary tumors cannot be excluded; 8.The patient requests to withdraw from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival (PFS); | — |
Countries
China
Contacts
Public ContactZhuomin Yin
Zhejiang Cancer Hospital
Outcome results
None listed